key: cord-0914317-gn0j6dis authors: Ghorbani, Mahdi; Brooks, Bernard R.; Klauda, Jeffery B. title: Exploring dynamics and network analysis of spike glycoprotein of SARS-COV-2 date: 2021-03-09 journal: Biophys J DOI: 10.1016/j.bpj.2021.02.047 sha: 716db222c3af338c7e5a36ddbc1d37c0ea913536 doc_id: 914317 cord_uid: gn0j6dis The ongoing pandemic caused by coronavirus SARS-COV-2 continues to rage with devastating consequences on human health and global economy. The spike glycoprotein on the surface of coronavirus mediates its entry into host cells and is the target of all current antibody design efforts to neutralize the virus. The glycan shield of the spike helps the virus to evade the human immune response by providing a thick sugar-coated barrier against any antibody. To study the dynamic motion of glycans in the spike protein, we performed microsecond-long MD simulation in two different states that correspond to the receptor binding domain in open or closed conformations. Analysis of this microsecond-long simulation revealed a scissoring motion on the N-terminal domain of neighboring monomers in the spike trimer. Role of multiple glycans in shielding of spike protein in different regions were uncovered by a network analysis, where the high betweenness centrality of glycans at the apex revealed their importance and function in the glycan shield. Microdomains of glycans were identified featuring a high degree of intra-communication in these microdomains. An antibody overlap analysis revealed the glycan microdomains as well as individual glycans that inhibit access to the antibody epitopes on the spike protein. Overall, the results of this study provide detailed understanding of the spike glycan shield, which may be utilized for therapeutic efforts against this crisis. Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) has rapidly spread worldwide since early 2020 and has been considered one of the most challenging global health crises within the century. SARS-COV-2 has caused more than 100 million cases and more than 2 million deaths worldwide as of February 2021.(1-3) Drug and vaccine development are underway and multiple vaccines have entered clinical trials and some of them are in the last stages of development. (4) (5) (6) SARS-COV-2 is a lipid-enveloped single stranded RNA virus belonging to the beta-coronavirus family, which also includes MERS, SARS and bat related coronaviruses. (7) (8) (9) (10) A major characteristic of all coronaviruses is the spike protein (S), which protrudes outward from the viral membrane and plays a key role in the entry of the pathogen into the host cells by binding to human angiotensin converting enzyme-2 (h-ACE2). (7, (11) (12) (13) The structure of each monomer of the trimeric spike protein in SARS-COV-2 ( Figure 1 ) can be divided into two subunits (S1 and S2), which can be cleaved at residues 685-686 (furin cleavage site) by TMPRSS protease after binding to host cell receptor h-ACE2.(13) S1 subunit in S trimer includes a N-terminal domain (NTD) and a receptor binding domain (RBD) that is responsible for binding to h-ACE2. (14) S2 subunit contains fusion peptides (FP), heptad repeats (HR1 and HR2), a transmembrane (TM) and a cytoplasmic domain (CP). The homotrimeric spike protein is highly glycosylated with 22 predicted N-linked glycosylation and 4 O glycosylation sites per monomer, most of which are confirmed by Cryo-EM studies. (15) (16) (17) (18) Glycosylation of proteins plays a crucial role in numerous biological process such as protein folding and evasion of immune response. (19) The receptor binding domain (RBD) of SARS-COV-2 binds to its receptor h-ACE2 with a significantly higher affinity than the earlier SARS coronavirus which is suggested to be the reason for its higher infection rate than SARS-COV in [2002] [2003] . (20) A receptor binding motif (RBM) in RBD makes all the contacts with the receptor by binding its concave surface to the convex exposed surface of h-ACE2. (21) Details of interaction between RBD of SARS-COV-2 and h-ACE2 are studied by us and by other groups, which showed that RBD of SARS-COV-2 binds to h-ACE2 with about 30 kcal/mol higher affinity than SARS-COV RBD. Mutations at critical residues from SARS to SARS-COV-2 RBM are suggested to the be the reason for the higher affinity. (20, 22) Natural mutations at the RBM of SARS-COV-2 have been found in multiple countries, which are not known to be linked with the severity of coronavirus. (23) In an earlier study, we have shown that most of these mutations in RBM do not affect the binding affinity of SARS-COV-2 RBD to h-ACE2 demonstrating the high tolerance of the interface for mutations. Our analysis showed the high contribution of critical residues K417, Q493, Q498 and G502 of RBM in SARS-COV-2 for its high binding affinity. In addition, our alanine scanning of interface residues in nCOV-2019 RBD showed that alanine substitution at some residues such as G502, K417 and L455 can significantly decrease the binding affinity of the complex. (20) The spike protein in SARS-COV-2 is highly glycosylated with 22 N-linked glycosylation sites and 4 O-linked glycosylation sites. (15) (16) (17) Glycosylation of the spike proteins plays a major role in evading the J o u r n a l P r e -p r o o f humoral immune system by cloaking the S protein by a thick shield of glycans. (24, 25) For example, the HIV-1 envelope glycoprotein (Env) features about 93 N-linked glycosylation sites with mostly high mannose glycans (Man5-9), which covers most of the surface of the spike protein in HIV-1 and comprises over half its mass. (3, 26, 27) N-linked glycosylation starts with synthesis of precursor oligosaccharides, which are modified to high mannose forms by glucosidases and then trimmed to complex forms in the Golgi by glucosyltransferases for signaling and other glycobiological functions.(28) A higher degree of processing is usually indicative of exposure or accessibility of glycans to enzymes.(3) Dense crowding glycan regions limit the activity of processing enzymes at these locations. In this study, we report the microsecond long MD simulation of all-atom solvated fully glycosylated spike protein embedded in a viral membrane model in both RBD-up or open state (PDB:6VSB)(11) and RBD-down (PDB:6VXX) (14) or closed state. The structure of the two states for glycosylated S protein in viral membrane were taken from the CHARMM-GUI website for this study. (16) Details of modeling different regions were presented in detail by Im and coworkers. (16) Structural changes in the spike protein happens on the order of microsecond timescale, where a scissoring motion is observed between the NTDs in the RBD-up conformation. We have used network analysis and centrality measures in graph theory to pinpoint the structural features of the glycan shield in the context of glycan-glycan interactions as well as binding of antibodies to the spike protein. A modularity algorithm helped us to find glycan microdomains featuring high glycan-glycan interactions with breaches between microdomains for antibodies to bind and neutralize the virus. Molecular dynamics simulation: Structures for glycosylated spike protein in the viral membrane with RBD-up and RBD-down states were taken from the CHARMM-GUI website (http://www.charmmgui.org/docs/archive/covid-19). Im et. al. (16) provided 8 different structures of spike protein in open and closed conformation where two models were built for heptad repeat linker (HR2), two models for the HR2-TM domain and two models for the cytoplasmic (CP) region. We used model 1_2_1 in which the missing loops for RBD were built by template-based modeling and N-terminal loop was constructed based on electron density map. Ab initio monomer structure prediction and ab initio trimer docking were used for the HR2 linker domain using PDB:5SZS(29) from SARS-COV-1 where two models were built (model 1 used here). Two models were constructed for HR2-TM junction using PDB:5JYN(30) as template, a model using a template structure (model 2 used here) and another model with more structural differences. Finally, the Cys-rich CP domain was constructed using PDB:5L5K(31) as a template. and NTD (residues 13 to 310) Network analysis: In the glycan network, each glycan is represented with a node (69 nodes for 69 glycans). To assign edges between nodes in the graph we first calculated the distance between heavy atoms of different glycans in the starting structure and if the distance between two glycan heavy atoms is less than 50 Å, an edge is assigned between the two nodes. Next to incorporate simulation data and dynamics of glycans into the network, we calculated the absolute value of average non-bonded interaction energy between every two glycans and normalized the values to be between 0 and 1 and assigned the as the edge weights. To simplify the network, we removed the edges with weights less than 0.05. This further reduced the number of edges form the starting graph. These normalized interaction energies represent the adjacency matrix for the graph from which different centrality measurements can be made. Two different centrality measurements were used to analyze the network of glycans. Betweenness centrality quantifies the number of times a node acts as a bridge along the shortest path connecting every two nodes in the graph and is an important indicator of the influence of the node within the network. Eigenvector centrality measures the node's importance in the network by considering the importance of the neighbors of that node. If the node is connected to many other nodes that are themselves well connected, that node is assigned a high eigenvector centrality score. For a graph with adjacency matrix A, the relative centrality score of the node i is defined as: The sum is over all j such that nodes i and j are connected. To write this in a matrix form let x be the vector containing the centrality scores and A be the adjacency matrix. Then we can write = With a constraint that all the components of the eigenvector x be positive, there is only one eigenvalue that satisfies the equation and therefore a unique centrality score is assigned to each node in the graph. A modularity algorithm in Gephi was used to find glycan microdomains that have high number of edges. All network analysis was performed in networkx and graph visualizations were done using Gephi. (44) (45) (46) Glycan-antibody overlap analysis: Antibodies that bind and neutralize spike protein are divided into three categories: (47) antibodies that bind to the exposed part of RBD (RBM-binder), antibodies that bind to epitopes away from the RBM in RBD or RBD-binder and antibodies that bind to epitopes on NTD (NTD-binder Dynamical motions of the spike protein: The root-mean-square deviation (RMSD) for each region of the spike protein in RBD-up and RBD-down states are represented in Figure S1 . SASA than closed using different probe sizes. Moreover, using a probe radius of 7.2 Å they showed that RBD has a lower SASA than RBM and NTD which is consistent with the findings in our study. A network analysis was carried out on the glycan shield of the spike protein in both RBD-up and RBD-down states to find the glycans that are most important for an effective shield. This approach has recently been applied to the glycan shield of HIV-1 spike protein. BCs were calculated for glycans in these clusters and changes in betweenness centrality ΔBC were measured between these networks of glycans built on different clusters ( Figure S6C and D) . NTD-binder antibodies can also bind to epitopes on the NTD of spike protein. These antibodies showed high number of clashes with glycans N74 and N149 of the respective monomer that they bind. Experimental studies are needed to explore the effect of deletion of these glycans on the neutralization effect by antibodies. The glycans on the surface of spike protein exert a collective behavior, which is an important property that needs to be considered in the context of vaccine and antibody design. In this work, we have studied the microsecond time dynamics and network analysis of the A pneumonia outbreak associated with a new coronavirus of probable bat origin A novel coronavirus from patients with pneumonia in China Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review Structural and functional basis of SARS-CoV-2 entry by using human ACE2 Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan Origin and evolution of pathogenic coronaviruses Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein Site-specific glycan analysis of the SARS-CoV-2 spike Developing a fully glycosylated full-length SARS-CoV-2 spike protein model in a viral membrane Deducing the N-and Oglycosylation profile of the spike protein of novel coronavirus SARS-CoV-2 Virus-receptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor Glycosylation in health and disease Critical Sequence Hotspots for Binding of Novel Coronavirus to Angiotensin Converter Enzyme as Evaluated by Molecular Simulations Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor Is the Rigidity of SARS-CoV-2 Spike Receptor-Binding Motif the Hallmark for Its Enhanced Infectivity? Insights from All-Atoms Simulations Data, disease and diplomacy: GISAID's innovative contribution to global health Vulnerabilities in coronavirus glycan shields despite extensive glycosylation Exploitation of glycosylation in enveloped virus pathobiology Quantification of the impact of the HIV-1-glycan shield on antibody elicitation Structure and immune recognition of the HIV glycan shield Effects of N-glycosylation on protein conformation and dynamics: Protein Data Bank analysis and molecular dynamics simulation study Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy Structural basis for membrane anchoring of HIV-1 envelope spike Structural basis for plexin activation and regulation Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone ϕ, ψ and side-chain χ1 and χ2 dihedral angles Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types CHARMM additive all-atom force field for carbohydrate derivatives and its utility in polysaccharide and carbohydrate-protein modeling GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers CHARMM-GUI: a web-based graphical user interface for CHARMM On the Berendsen thermostat Pressure coupling/barostats Polymorphic transitions in single crystals: A new molecular dynamics method The nose-hoover thermostat Particle mesh Ewald: An N⋅ log (N) method for Ewald sums in large systems VMD: visual molecular dynamics Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein Fast unfolding of communities in large networks Exploring network structure, dynamics, and function using NetworkX Gephi: an open source software for exploring and manipulating networks Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 Structural and functional analysis of a potent sarbecovirus neutralizing antibody A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 Map of SARS-CoV-2 spike epitopes not shielded by glycans situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges. Science Molecular architecture of the SARS-CoV-2 virus Beyond shielding: the roles of glycans in the SARS-CoV-2 spike protein Microsecond dynamics and network analysis of the HIV-1 SOSIP Env trimer reveal collective behavior and conserved microdomains of the glycan shield Quantification of the Resilience and Vulnerability of HIV-1 Native Glycan Shield at Atomistic Detail Visualization of the HIV-1 Env glycan shield across scales 2020. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor Defining HIV-1 envelope N-glycan microdomains through sitespecific heterogeneity profiles The simulation trajectories, pdb and psf of open and closed spike conformations embedded in viral membrane are uploaded to MolSSI database and can be downloaded at: https://molssi-bioexcelcovid-19-structure-therapeutics-hub.s3.amazonaws.com/KlaudaGroup/spike_6VXX_1_2_1_nowater.gz and https://molssi-bioexcel-covid-19-structuretherapeuticshub.s3.amazonaws.com/KlaudaGroup/spike_6VSB_1_2_1_nowater.gz